Abstract:Hemophilia B (HB) is an X-linked recessive bleeding disorder, caused by F9 gene deficiency. Gene therapy combined with the CRISPR/Cas9 technology offers a potential cure for hemophilia B. Now the Cas9 nickase (Cas9n) shows a great advantage in reducing off-target effect compared with wild-type Cas9. In this study, we found that in the multicopy ribosomal DNA (rDNA) locus, the homology directed recombination (HDR) efficiency induced by sgRNA-Cas9n was much higher than sgRNA-Cas9, meanwhile without off-target in six predicted sites. After co-transfection into mESCs with sgRNA-Cas9n and a non-viral rDNA targeting vector pMrnF9, harboring the homology donor template and the human F9 expression cassette, a recombination efficiency of 66.7% was achieved and all targeted clones were confirmed to be site-specific integration of F9 in the rDNA locus by PCR and southern blotting. Targeted mESCs retained the main pluripotent properties and were then differentiated into hepatic progenitor like cells (HPLCs) and mature hepatocytes, which were characterized by hepatic markers and functional assays. Importantly, the differentiated cells could transcribe exogenous F9 and secrete coagulation factor IX (FIX) proteins, suggesting active transcription and stable inheritance of transgenes in the rDNA locus. After intrasplenical transplantation in severe combined immune deficiency (SCID) mice, targeted HPLCs could survive and migrate from spleen to liver, resulting in secretion of exogenous FIX into blood. In summary, we demonstrate an efficient and site-specific gene targeting strategy in rDNA locus for stem cell-based gene therapy for hemophilia B.

Long-term Correction of Hemophilia B Through CRISPR/Cas9 Induced Homology-Independent Targeted Integration

Long-term correction of haemophilia B through CRISPR/Cas9 induced homology-independent targeted integration

CRISPR-Mediated in Situ Introduction or Integration of F9-Padua in Human Ipscs for Gene Therapy of Hemophilia B.

CRISPR-Cas9-Mediated in Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice.

CRISPR/Cas9-mediated Somatic and Germline Gene Correction to Restore Hemostasis in Hemophilia B Mice

Low-dose AAV-CRISPR-mediated Liver-Specific Knock-in Restored Hemostasis in Neonatal Hemophilia B Mice with Subtle Antibody Response

Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion

Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse

CRISPR/Cas9‐mediated Somatic Correction of a Novel Coagulator Factor IX Gene Mutation Ameliorates Hemophilia in Mouse

Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of F9 into rDNA Locus of Mouse ESCs

Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of into rDNA Locus of Mouse ESCs.

CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A

CRISPR/Cas9-mediated Knockin of Human Factor IX into Swine Factor IX Locus Effectively Alleviates Bleeding in Hemophilia B Pigs

Delivery of Cas9-guided ABE8e into stem cells using poly(l-lysine) polypeptides for correction of the hemophilia-associated FIX missense mutation

Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro

Targeted Genome Engineering in Human Induced Pluripotent Stem Cells from Patients with Hemophilia B Using the CRISPR-Cas9 System

Gene Therapy for Hemophilia B with Liver-specific Element Mediated by Rep-RBE Site-specific Integration System

[Human coagulation factor IX gene therapy in murine hemophilia B by hydrodynamic delivery and site-specific genomic integration]

In Vivo CRISPR/Cas9-Targeted Genome Editing Recovers Factor IX Expression Restoring Haemostasis in a Mouse Model

Rescue of the endogenous FVIII expression in hemophilia A mice using CRISPR-Cas9 mRNA LNPs

Correction of F8 intron 1 inversion in hemophilia A patient-specific iPSCs by CRISPR/Cas9 mediated gene editing